Montclair, NJ, and Oxford, MS ― March 19, 2014 ― “Payers: Managing More or Caring More?” will be the topic when MME’s Jack Mycka (Global President, CEO & Partner) and Doug Paul, PharmD, Ph.D. (Partner), square off in one of the friendly sparring matches in Innovation Lab’s The Great Orphan Drug Debate ’14 on Thursday, April 24, 2014, at Bobby Van’s Grill in Washington, DC, following the first day of the World Orphan Drug Congress.
Mycka and Paul, both with a wealth of experience in pharmaceutical marketing—and rare disease therapies in particular—will cover issues such as payers’ handling of new therapies for rare diseases, whether there are restrictions, and whether prices are affecting coverage decisions. They will also discuss possible differences around the world and what tools payers may leverage to manage these therapies.
Another debate, “The Patient Versus the HCP—Who Really Holds the Decision Power?” will feature Peter Nalen, President/CEO, and Paul Johnson, EVP Client Services, Compass Healthcare Marketers.
To learn more or to register for the dinner event, please visit The Great Debate site
To learn more about the World Orphan Drug Congress, please visit the WODC registration page
For additional information about Medical Marketing Economics, please contact us at +1 662.281.0502 or via e-mail at info@m2econ.com.
